Detailed Information

Cited 4 time in webofscience Cited 6 time in scopus
Metadata Downloads

Patterns and Outcomes in Hepatocellular Carcinoma Patients with Portal Vein Invasion: A Multicenter Prospective Cohort Study

Authors
Sinn, Dong HyunLee, Hye WonPaik, Yong-HanKim, Do YoungKim, Yoon JunKim, Kang MoBae, Si HyunKim, Ji HoonSeo, Yeon SeokJang, Jae YoungJang, Byoung KukYim, Hyung JoonKim, Hyung JoonLee, Byung SeokKim, Bo HyunKim, In HeeCho, Eun-YoungLee, Jung IlSuh, Kyung-Suk
Issue Date
Jan-2021
Publisher
SPRINGER
Keywords
Hepatocellular carcinoma; Portal vein invasion; Cohort
Citation
Digestive Diseases and Sciences, v.66, no.1, pp.315 - 324
Indexed
SCIE
SCOPUS
Journal Title
Digestive Diseases and Sciences
Volume
66
Number
1
Start Page
315
End Page
324
URI
https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/49196
DOI
10.1007/s10620-020-06134-4
ISSN
0163-2116
Abstract
Background and Aims Sorafenib is a proven first-line treatment recommended for hepatocellular carcinoma (HCC) patients with portal vein invasion (PVI). However, multiple treatment modalities are used in clinical practice as a first-line option. This study is a prospective, observational, multicenter, cohort study evaluating patterns of treatment modalities and outcomes for HCC patients with PVI. Methods The baseline characteristics, treatment modalities, and outcomes were prospectively collected for 287 newly diagnosed HCC patients with PVI between August 2015 and July 2016 from 16 sites in Korea. Results During a median 7.8 months of follow-up (range 0.3–24.6 months), mortality was observed in 123 (42.9%) patients. Decision tree analysis classified patients into five subgroups with different outcomes. The patterns of treatment were very heterogeneous, and there was no dominant treatment modality. The most commonly used treatment modality was transarterial chemoembolization (TACE) (20.2%) followed by TACE plus external beam radiation therapy (17.8%) and sorafenib (12.5%). When stratified according to the extent of PVI, sorafenib treatment showed comparable outcomes when the PVI extent was lobal or main/bilateral, yet showed worse outcomes when the PVI extent was limited to the segmental level compared to those who received treatment other than sorafenib. Conclusions HCC patients with PVI comprise a heterogeneous population and are treated with various treatment modalities with diverse clinical outcomes in clinical practice. Subclassification of HCC patients with PVI is required to minimize heterogeneity and should be considered for the selection of treatment modalities and future clinical trials.
Files in This Item
There are no files associated with this item.
Appears in
Collections
2. Clinical Science > Department of Gastroenterology and Hepatology > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher Yim, Hyung Joon photo

Yim, Hyung Joon
Ansan Hospital (Department of Gastroenterology and Hepatology, Ansan Hospital)
Read more

Altmetrics

Total Views & Downloads

BROWSE